New therapeutic agents for the treatment of bone diseases

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

Bisphosphonates have demonstrated important clinical benefits for patients with malignant bone disease, metabolic bone diseases, such as Paget's disease, and postmenopausal osteoporosis. The introduction of nitrogen-containing bisphosphonates with high affinity for hydroxyapatite in bone represents an important advancement. These agents are now a standard of care for osteoporosis, Paget's disease, osteogenesis imperfecta, primary bone lesions from multiple myeloma and bone metastases from breast cancer. Moreover, the recent clinical development of zoledronic acid (4 mg by 15-minute intravenous infusion) has expanded the benefits of bisphosphonate therapy to patients with bone metastases from any solid tumour. Bisphosphonates are also being investigated at present for the prevention of bone loss resulting from cancer therapy. In addition, a variety of novel biologic agents, receptor activator of nuclear factor-κB (RANK) ligand antibodies, osteoprotegerin and cathepsin K inhibitors are being investigated at present for the treatment of malignant bone disease. The management of bone health is an important area of active research, and the armamentarium and role of bone-specific therapies continue to expand.

Original languageEnglish (US)
Pages (from-to)817-832
Number of pages16
JournalExpert Opinion on Biological Therapy
Volume5
Issue number6
DOIs
StatePublished - Jun 1 2005

Fingerprint

Bone Diseases
Bone
Bone and Bones
Diphosphonates
zoledronic acid
Therapeutics
Cathepsin K
Neoplasm Metastasis
RANK Ligand
Osteoprotegerin
Osteogenesis Imperfecta
Postmenopausal Osteoporosis
Metabolic Bone Diseases
Biological Factors
Durapatite
Standard of Care
Cytoplasmic and Nuclear Receptors
Multiple Myeloma
Intravenous Infusions
Osteoporosis

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

@article{beb2bded8ee44bd5b17379998a223339,
title = "New therapeutic agents for the treatment of bone diseases",
abstract = "Bisphosphonates have demonstrated important clinical benefits for patients with malignant bone disease, metabolic bone diseases, such as Paget's disease, and postmenopausal osteoporosis. The introduction of nitrogen-containing bisphosphonates with high affinity for hydroxyapatite in bone represents an important advancement. These agents are now a standard of care for osteoporosis, Paget's disease, osteogenesis imperfecta, primary bone lesions from multiple myeloma and bone metastases from breast cancer. Moreover, the recent clinical development of zoledronic acid (4 mg by 15-minute intravenous infusion) has expanded the benefits of bisphosphonate therapy to patients with bone metastases from any solid tumour. Bisphosphonates are also being investigated at present for the prevention of bone loss resulting from cancer therapy. In addition, a variety of novel biologic agents, receptor activator of nuclear factor-κB (RANK) ligand antibodies, osteoprotegerin and cathepsin K inhibitors are being investigated at present for the treatment of malignant bone disease. The management of bone health is an important area of active research, and the armamentarium and role of bone-specific therapies continue to expand.",
author = "Allan Lipton",
year = "2005",
month = "6",
day = "1",
doi = "10.1517/14712598.5.6.817",
language = "English (US)",
volume = "5",
pages = "817--832",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "6",

}

New therapeutic agents for the treatment of bone diseases. / Lipton, Allan.

In: Expert Opinion on Biological Therapy, Vol. 5, No. 6, 01.06.2005, p. 817-832.

Research output: Contribution to journalReview article

TY - JOUR

T1 - New therapeutic agents for the treatment of bone diseases

AU - Lipton, Allan

PY - 2005/6/1

Y1 - 2005/6/1

N2 - Bisphosphonates have demonstrated important clinical benefits for patients with malignant bone disease, metabolic bone diseases, such as Paget's disease, and postmenopausal osteoporosis. The introduction of nitrogen-containing bisphosphonates with high affinity for hydroxyapatite in bone represents an important advancement. These agents are now a standard of care for osteoporosis, Paget's disease, osteogenesis imperfecta, primary bone lesions from multiple myeloma and bone metastases from breast cancer. Moreover, the recent clinical development of zoledronic acid (4 mg by 15-minute intravenous infusion) has expanded the benefits of bisphosphonate therapy to patients with bone metastases from any solid tumour. Bisphosphonates are also being investigated at present for the prevention of bone loss resulting from cancer therapy. In addition, a variety of novel biologic agents, receptor activator of nuclear factor-κB (RANK) ligand antibodies, osteoprotegerin and cathepsin K inhibitors are being investigated at present for the treatment of malignant bone disease. The management of bone health is an important area of active research, and the armamentarium and role of bone-specific therapies continue to expand.

AB - Bisphosphonates have demonstrated important clinical benefits for patients with malignant bone disease, metabolic bone diseases, such as Paget's disease, and postmenopausal osteoporosis. The introduction of nitrogen-containing bisphosphonates with high affinity for hydroxyapatite in bone represents an important advancement. These agents are now a standard of care for osteoporosis, Paget's disease, osteogenesis imperfecta, primary bone lesions from multiple myeloma and bone metastases from breast cancer. Moreover, the recent clinical development of zoledronic acid (4 mg by 15-minute intravenous infusion) has expanded the benefits of bisphosphonate therapy to patients with bone metastases from any solid tumour. Bisphosphonates are also being investigated at present for the prevention of bone loss resulting from cancer therapy. In addition, a variety of novel biologic agents, receptor activator of nuclear factor-κB (RANK) ligand antibodies, osteoprotegerin and cathepsin K inhibitors are being investigated at present for the treatment of malignant bone disease. The management of bone health is an important area of active research, and the armamentarium and role of bone-specific therapies continue to expand.

UR - http://www.scopus.com/inward/record.url?scp=21044453588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21044453588&partnerID=8YFLogxK

U2 - 10.1517/14712598.5.6.817

DO - 10.1517/14712598.5.6.817

M3 - Review article

VL - 5

SP - 817

EP - 832

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 6

ER -